Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
1.180
+0.010 (0.85%)
At close: Sep 17, 2025, 4:00 PM EDT
1.190
+0.010 (0.85%)
After-hours: Sep 17, 2025, 6:24 PM EDT

Citius Pharmaceuticals Stock Forecast

CTXR's stock price has decreased by -90.65% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts that cover Citius Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $53, which forecasts a 4,391.53% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $100.

Price Target: $53 (+4,391.53%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$6.00$53$100$100
Change+408.47%+4391.5%+8374.6%+8374.6%
* Price targets were last updated on Aug 13, 2025.

Analyst Ratings

The average analyst rating for Citius Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingApr '25May '25Jun '25Jul '25Aug '25Sep '25
Strong Buy222222
Buy000000
Hold011111
Sell000000
Strong Sell000000
Total233333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$6
Strong BuyMaintains$6+408.47%Aug 13, 2025
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$6
Strong BuyMaintains$6+408.47%Jun 30, 2025
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$9$6
Strong BuyMaintains$9$6+408.47%Jun 10, 2025
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$9
Strong BuyMaintains$9+662.71%Jun 9, 2025
Maxim Group
Maxim Group
Hold
Downgrades
n/a
HoldDowngradesn/an/aMay 23, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
7.83M
Revenue Next Year
74.50M
from 7.83M
Increased by 851.67%
EPS This Year
-3.72
from -5.97
EPS Next Year
0.37
from -3.72
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingSep 30, 2020Sep 30, 2021Sep 30, 2022Sep 30, 2023Sep 30, 2024Sep 30, 2025Sep 30, 2026
Revenue
-----7.83M74.50M
Revenue Growth
------851.67%
EPS
-11.20-5.64-5.76-5.57-5.97-3.720.37
EPS Growth
-------
Forward PE
------3.21
No. Analysts
-----55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027202820292030
High16.1M82.2M
Avg7.8M74.5M
Lown/a66.4M

Revenue Growth

Revenue Growth202520262027202820292030
High-
950.1%
Avg-
851.7%
Low-
748.6%

EPS Forecast

EPS202520262027202820292030
High-3.422.00
Avg-3.720.37
Low-3.96-0.61

EPS Growth

EPS Growth202520262027202820292030
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.